
This week, phage and antibiotic treatment for resistant Pseudomonas infections, concerns over SEP-1’s impact on sepsis management, and ongoing measles outbreak signaling declining vaccination rates.
This week, phage and antibiotic treatment for resistant Pseudomonas infections, concerns over SEP-1’s impact on sepsis management, and ongoing measles outbreak signaling declining vaccination rates.
With the release of these guidelines and the US Health and Human Services canceling the mid-March FDA VRBPAC meeting to discuss these vaccine recommendations, Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), offers insight on these developments.
A spokesperson from the UK Health Security Agency highlighted key updates in the 2024 UK-AWaRe classification, aligning them with national AMR goals.
The interim results demonstrated a slightly better vaccine effectiveness in individuals who are immunocompetent vs immunocompromised individuals.
New study by Gabriel Nussbaum, MD, PhD, et al, reveals how P gingivalis escapes immune detection, contributing to gum disease and increasing risks for systemic infections such as respiratory disease.
The state’s health department has confirmed all 3 cases are in people who are unvaccinated.
Erlinda Ulloa, MD, discusses a severe case including how they secured the phage treatment, and her experience with the investigational therapy.
The most recent CDC report accounts for 33 million flu illnesses, 430,000 hospitalizations, and 19,000 deaths this flu season, with Influenza A(H1N1) and A(H3N2) as the primary strains.
The CDC tracks rising human infections linked to poultry and dairy exposure, while the USDA steps up with a comprehensive strategy to combat HPAI and stabilize egg prices.
On the heels of the first death in an ongoing US-based measles outbreak, Paul Offit, MD, discusses how outbreaks are the first sign that childhood vaccination rates are starting to decline.
A multistate Listeria outbreak has resulted in 38 cases, 37 hospitalizations, and 12 deaths, prompting a recall and ongoing investigation by the FDA and CDC.
Ken Duncan, PhD, discussed the launch of a $50 million initiative focused on developing new drugs for critical pathogens contributing to antimicrobial resistance.
This region of Africa, which has been beset by mpox, malaria, Ebola, and Marburg disease is also seeing a mysterious illness with several hundred reported cases in 2 villages in Africa.
Todd Riccobene, PhD, senior scientific director, Anti-Infectives and Infectious Diseases, US Medical Affairs + Health Impact at AbbVie provides more information on the newly approved antibiotic combination for these infections.
James Ford, MD, MAS, discusses the evidence supporting SEP-1’s impact on sepsis mortality and suggests alternative approaches focused on outcome-based measures in sepsis management.
Tina Tan, MD, FIDSA, FPIDS, FAAP, Infectious Diseases Society of America (IDSA) president discusses the changes and offers a glimpse of what the US can expect in terms of limited access to new vaccines, increased incidence rates of disease, and new public health policy regarding immunizations.
Jeffrey Freiberg, MD, PhD review of the SABATO trial on oral antibiotics for S aureus bacteremia and a comparison of mupirocin and iodine treatments for MRSA decolonization.
The World Health Organization (WHO) reports on the vaccine uptake in that region, and the Global Polio Eradication Initiative reports that some countries recording new cases.
Jaime Garcia-Iglesias, PhD discusses community involvement, holistic benefits, and strategies for equitable rollout of doxycycline post-exposure prophylaxis.
The company announced its monoclonal antibody, pemivibart (Pemgarda), was denied the emergency use authorization (EUA) for treatment of mild-to-moderate COVID-19 for immunocompromised persons.
Jeffery Freiberg, MD, PhD review on key trials and challenges from 2024 in the fight against antibiotic resistance in complicated and uncomplictaed UTIs, including cefepime-taniborbactam and gepotidacin.
Here are some strategies to consider for optimal utilization.
This week, the FDA set a target date for lenacapavir’s approval, as rising cases of dengue, measles, and other emerging threats continue to spread, alongside a dairy worker transmitting avian flu to his cats.
Chinese researchers say this newly discovered virus can be transmitted to humans much the way COVID-19 did.
The fixed-dose combination will be used outside the EU to treat soil-transmitted helminths and lymphatic filariasis.
Jeff Freiberg, MD, PhD, on the rising emerging infection concerns of dengue, mpox, measles, and H5N1 influenza in clinical practice.
Two cats became severely ill, and both owners declined to be tested.
A new study published in JAMA Network Open points out that immunization also occurred in individuals who did not receive routine prenatal or infant vaccines.
Andrew Engeli explains Ginkgo's role in the €24 million EU-Funded RANGER project for emerging infectious disease surveillance and response.
In a novel, natural experiment associated with age and the antiviral, investigators were able to see the effects of the therapy in a group of adults considered to be more at risk for hospitalization and death.